AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5%
Fri, 7 Feb

AUROBINDO PHARMA has announced its results for the quarter ended December 2019. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Dec-18*
3
Sep-19*
3
Dec-19*
QoQ ChangeYoY Change
Net SalesRs m52,69756,00557,9943.6%10.1%
Other incomeRs m63920630950.0%-51.6%
TurnoverRs m53,33556,21158,3043.7%9.3%
ExpensesRs m41,83344,60346,8705.1%12.0%
Gross profitRs m10,61311,27511,9516.0%12.6%
DepreciationRs m1,6312,4332,5012.8%53.3%
InterestRs m477409371-9.4%-22.1%
Profit before taxRs m9,1448,6389,3888.7%2.7%
TaxRs m2,0482,2442,3293.8%13.7%
Profit after taxRs m7,0966,3957,06010.4%-0.5%
Gross profit margin%20.120.120.6
Effective tax rate%22.426.024.8
Net profit margin%13.311.412.1
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 10.1% on a year-on-year (YoY) basis. The expenses were up by 12.0% YoY during the same period.
  • The company's operating profit increased by 12.6% YoY during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.6% in 3QFY20 as against 20.1% in 3QFY19.
  • Depreciation charges increased by 53.3% and finance costs declined by 22.1% YoY, respectively.
  • Other income declined by 51.6% YoY during the quarter.
  • Net profit for the quarter declined by 0.5% YoY. Net profit margins during the quarter declined from 13.3% in 3QFY19 to 12.1% in 3QFY20.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 3.6% on a quarter-on-quarter (QoQ) basis. The expenses were up by 5.1% QoQ during the same period.
  • The company's operating profit increased by 6.0% QoQ during the quarter. Consequently, operating profit margins witnessed a growth and stood at 20.6% in 3QFY20 as against 20.1% in 2QFY19.
  • Net profit for the quarter increased by 10.4% QoQ, while net profit margins increased from 11.4% in 2QFY19 to 12.1% in 3QFY20.

To see how AUROBINDO PHARMA has performed over the last eight quarters,please visit here.

Only Till 11:59PM, Tomorrow: Access Details of Our Top Stock Pick for 2021

AUROBINDO PHARMA Share Price Performance

Over the last one year,AUROBINDO PHARMA share price has moved down from Rs 778.8 to Rs 550.2, registering a Loss of Rs 228.6 or around 29.4%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 14,243.4 (up 1.3%). Over the last one year it has moved up from 14,067.5 to 14,243.4, a gain of 176 points (up 1.3%).

Overall, the S&P BSE SENSEX is up 11.3% over the year.

Current Valuations

At the current price of Rs 550.2, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 12.6 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 2.3 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers(Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff(Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200?(Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now?(Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 29, 2020 03:37 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - GLENMARK PHARMA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS